Table 2.
Frequencies of contralateral breast cancer patients CBC carrying apathogenic DNA-damage repair pathway mutation
| Parameter | Breast cancer < 50 yearsa (percentage) | All CBC patients (n = 247) | Previous RT (n = 169) | No RT (n = 78) | Carriers versus non-carriers | |||||
| n | Percentage | n | Percentage | n | Percentage | OR for CBC after RT | 95% CI | p | ||
| DDRP mutated | ~10 | 51 | 21 | 41 | 24.3 | 10 | 12.8 | 2.18 | 1.03–4.62 | 0.043 |
| CHEK2 | 1–2 | 15 | 6.1 | 13 | 7.7 | 2 | 2.6 | 3.17 | 0.69–14.39 | |
| BRCA1 | ~4–5 | 27 | 11.3 | 20 | 11.8 | 7 | 9 | 1.36 | 0.55–3.37 | |
| BRCA2 | ~0.5–1 | 5 | 2 | 4 | 2.4 | 1 | 1.3 | 1.87 | 0.21–16.98 | |
| ATM truncating | ~1–2 | 4 | 1.6 | 4 | 2.4 | 0 | 0 | - | - | |
| 1b | 1.3 | 1.87 | 0.21–16.98 | |||||||
Results for all contralateral breast cancer (CBC) patients, and patients stratified by previous radiation exposure, are presented. Odds ratio (OR) and 95% confidence interval (CI) are given for mutation carriers versus non-carriers to develop radiation-associated breast cancer. DDRP, DNA-damage repair pathway; RT, radiation treatment. aPublished results; bHypothetical assumption of one case.